Quantum BioPharma Ltd. is trading 10.3% down at $4.38 as selling continues following a major regulatory setback for its lead multiple sclerosis candidate.
- The FDA recently placed a clinical hold on the company’s only meaningful pipeline asset, raising significant funding and survival concerns for the sub-micro-cap firm.
- The stock has now fallen more than 35% since late May as investors reassess risk amid the regulatory hold and recent management changes.